Change in Nuevolution’s Board of Directors
Stockholm, 2 February 2016. Nuevolution AB (publ) announces that Viktor Drvota has resigned as Director of Nuevolution’s board of directors
Viktor Drvota has taken up the position as Chief Investment Officer at Karolinska Development after having been Head of Life Science Venture at SEB Venture Capital. Therefore he resigned from the board of Nuevolution AB (publ). Viktor has been a member of Nuevolution’s Board of Directors since 2003.
“We would like to thank Viktor for his efforts made over the last 12 years. We expect to announce a replacement of Viktor in the near future”, commented Stig Løkke Pedersen, Chairman of the Board.
Information on Viktor Drvota’s resignation was registered on the 1 February 2016 by to the Swedish Companies Registration Office.
For more information, please contact:
Alex Haahr Gouliaev, CEO
Phone: +45 70 20 09 87
Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, and headquartered in Copenhagen, Denmark. Nuevolution partners its discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefit of patients in need of novel medical treatment option. Nuevolution’s internal programs are focused on therapeutically important targets within inflammation, oncology and immuno-oncology.
Nuevolution AB (publ) is required to disclose the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was send for publication on 2 February 2016, 12.30 (CET)